Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis
نویسندگان
چکیده
منابع مشابه
Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.
BACKGROUND AND PURPOSE Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment. METHODS Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 1...
متن کاملUpdate on a patient with superficial siderosis on deferiprone.
Deferiprone Superficial siderosis (SS) is a neurodegenerative condition caused by hemosiderin deposition on the surface of the brain, cranial nerves, and spinal cord. SS is an exceptionally rare condition characterized by a triad of hearing loss, ataxia, and myelopathy. The most common etiologies that lead to SS are trauma, previous surgical procedures, dural tears, and tumors of the central ne...
متن کاملDeferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.
A man with superficial siderosis showed improvement in symptoms and reduction in hemosiderin by MR imaging following treatment with deferiprone, a lipid-soluble iron chelator.
متن کاملSuperficial siderosis.
Case 1 An elderly patient presented with insidious onset of sensorineural hearing loss. The past history was unremarkable except for insidious onset of weakness of left lower limb. Physical examination revealed left hemiparesis with upgoing left plantar. Magnetic resonance imaging (MRI) of brain revealed a large flow void in the interpeduncular cistern suggestive of aneurysm arising from the to...
متن کاملRandomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators. A randomized controlled trial was performed in 61 patients previously maintained on subcutaneous deferoxamine. The primary end point was the change in myocardial siderosis (myocardial T2(*)) over 1 year in patients main...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2012
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.111.628032